Companies To Watch

The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.

  • Companies To Watch: Artax Biopharma

    Artax Biopharma is challenging the immunosuppressive paradigm with a novel drug for autoimmune diseases.

  • Companies To Watch: Ridgeback Biotherapeutics

    Ridgeback Biotherapeutics is pitting new and potent antivirals versus COVID, Ebola, and other coronaviruses.

  • Companies To Watch: Osivax

    Osivax is developing universal vaccines for influenza, coronaviruses, and other infectious diseases such as malaria and human papillomavirus (HPV). Preclinical studies also have started on a coronavirus vaccine, which would include Covid-19.

  • Companies To Watch: CalciMedica

    “In a sense, the Covid association was a golden opportunity for our drug,” says Rachel Leheny, CEO of CalciMedica, a pharma focused on anti-inflammatories for pancreatitis that has now shifted to treatments for Covid-19 pneumonia.

  • Companies To Watch: Cidara Therapeutics

    Cidara Therapeutics is training its novel treatment and preventative for flu and other viral infections on Covid-19.

  • Companies To Watch: Equillium

    Equillium is keeping a close eye on the COVID-19 challenge, but sticking to acute GVHD, uncontrolled asthma, and lupus nephritis as primary inflammation targets.

  • Companies To Watch: Spring Bank Pharmaceuticals

    Spring Bank Pharmaceuticals is continuing clinical programs during the COVID-19 challenge and advancing novel approaches to cancer, inflammation, and viruses.

  • Companies To Watch: argenx

    Argenx is developing new antibody therapeutics for immunological diseases in the neuromuscular, hematology, oncology, and other areas. The company has a full pipeline of candidates and indications.

  • Companies To Watch: Neurana

    This 10-person startup in San Diego is aiming for muscle-spasm relief without sedation in a purified drug.

  • Companies To Watch: Adaptive Phage Therapeutics

    Adaptive Phage Therapeutics has created a large catalog of bacteria-killing viruses combined with a diagnostic test to identify and target specific bacterial strains infecting individual patients.

  • Companies To Watch: Imago BioSciences

    In developing a new drug for MPN diseases, Imago is entering a space where two potential competitors, Jakafi and Inrebic, both JAK (janus associated kinase) inhibitors, are already on the market.

  • Companies To Watch: Scynexis

    Scynexis is creating multiple development programs and a new class of antifungals — all in a single, and singular, drug.

  • Companies To Watch: Obsidian Therapeutics

    Obsidian Therapeutics targets gene and cell therapies with a technology designed to control the production and activity of therapeutic proteins those therapies induce.

  • Companies To Watch: eXIthera

    This month’s company to watch is eXIthera, which is focused on inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants.

BEYOND THE PRINTED PAGE

  • What 4 Biopharma CFOs Think About The Future Of Remote Work

    While we touch on remote work in Life Science Leader’s annual outlook issue, the responses in this article from four biopharmaceutical CFOs to questions on the subject shed additional light on the challenge that lies ahead for employers.

  • Where Does Biopharma’s Future Reside Beyond Boston And San Francisco?

    Two metropolitan areas tend to dominate the discussion when it comes to key biopharmaceutical industry hubs within the United States — Boston and San Francisco. And while these two cities have certainly earned their biopharma bragging rights over the years, one has to wonder how long that will continue. Afterall, just a few years ago biopharmaceutical executives noted it becoming increasingly difficult to attract top talent, as candidates cited “too crowded,” “too expensive,” and a host of other reasons behind their unwillingness to move to places like Boston and San Francisco. But does location (for many roles) even still apply?

  • Why Treat The Eye Through The Nose?

    Jeffrey Nau, Ph.D., president and CEO of Oyster Point Pharma and subject of upcoming feature in Life Science Leader, explains the scientific rationale behind treating dry eye disease (DED) using nasal spray as a method of delivery. 

LIFE SCIENCE LEADER BLOGS

@LIFESCILEADER1